Skip to content
OpenCapital
Get started

Arcus Biosciences RCUS Quick ratio

Quick ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.3×+0.1×
Merck & Co. logo
Merck & Co.MRK
1.1×-0.2×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
3×-1.1×
AbbVie logo
AbbVieABBV
0.7×0.0×
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
10.7×-3.2×
Incyte logo
IncyteINCY
3.5×+1.6×

Other financials

Income statement

See full
Revenue$17.0M-39.3%
Operating income-$134.0M-9.8%
Net income-$128.0M-14.3%
EPS (diluted)-$1.02+10.5%

Balance sheet

See full
Cash & equivalents$201.0M+4.7%
Total debt$113.0M+88.3%
Total equity$524.0M-1.3%
Total assets$997.0M-13.8%

Cash flow

See full
Operating cash flow-$138.0M-4.5%
CapEx--100%
Free cash flow-$138.0M-3.8%

Valuation

See full
Market cap$3.54B+226%
Enterprise value$3.46B+275%
P/S15×+7.3×

Profitability

See full
Operating margin-168.6%-52.7pp
Net margin-156.4%-47.5pp
FCF margin-207.2%—

Returns & leverage

See full
Return on equity-70%+8.4pp
Debt / equity0.2×+0.1×
Current ratio4×-1.3×

Where this comes from

Calculated from Arcus Biosciences’s reported figures.

quick assets/total current liabilities=4×

Based on the most recent quarter.

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcus Biosciences's quick ratio?
Arcus Biosciences (RCUS) reported quick ratio of 4× in Q1 2026.
How has Arcus Biosciences's quick ratio changed year-over-year?
Arcus Biosciences's quick ratio decreased by 24.8% year-over-year, from 5.4× to 4×.
What is the long-term trend for Arcus Biosciences's quick ratio?
Over 5 years (2020 to 2025), Arcus Biosciences's quick ratio has grown at a -6.3% compound annual growth rate (CAGR), from 6× to 4.4×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.